

Atholl Johnston

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/376607/publications.pdf>

Version: 2024-02-01

245
papers

7,708
citations

50276

46
h-index

69250

77
g-index

246
all docs

246
docs citations

246
times ranked

6289
citing authors

#	ARTICLE	IF	CITATIONS
1	Analysis of illicit drugs in purchased and seized electronic cigarette liquids from the United Kingdom 2014–2021. <i>Drug Testing and Analysis</i> , 2023, 15, 1058-1066.	2.6	3
2	Limited sampling strategies for estimation of tacrolimus exposure in kidney transplant recipients receiving extended-release tacrolimus preparation. <i>Clinical and Translational Science</i> , 2022, 15, 70-78.	3.1	8
3	Quantification of mycophenolic acid in human plasma by liquid chromatography with time-of-flight mass spectrometry for therapeutic drug monitoring. <i>Biomedical Chromatography</i> , 2021, 35, e5011.	1.7	2
4	Simultaneous quantification of cyclosporin, tacrolimus, sirolimus and everolimus in whole blood by UHPLC-MS/MS for therapeutic drug monitoring. <i>Biomedical Chromatography</i> , 2021, 35, e5071.	1.7	6
5	IMMU-02. CH14.18 IN THE TREATMENT OF HIGH-RISK NEUROBLASTOMA: A META-ANALYSIS. <i>Neuro-Oncology</i> , 2021, 23, i27-i27.	1.2	0
6	Total body water is the preferred method to use in forensic blood-alcohol calculations rather than ethanol's volume of distribution. <i>Forensic Science International</i> , 2020, 316, 110532.	2.2	9
7	β -Lactam antimicrobial pharmacokinetics and target attainment in critically ill patients aged 1 day to 90 years: the ABDose study. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3625-3634.	3.0	13
8	Variability in content and dissolution profiles of MDMA tablets collected in the UK between 2001 and 2018 – A potential risk to users?. <i>Drug Testing and Analysis</i> , 2019, 11, 1172-1182.	2.6	23
9	Rapid Quantitation of Flecainide in Human Plasma for Therapeutic Drug Monitoring Using Liquid Chromatography and Time-of-Flight Mass Spectrometry. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 391-395.	2.0	7
10	Safety and Pharmacokinetics of Levobupivacaine Following Fascia Iliaca Compartment Block in Elderly Patients. <i>Drugs and Aging</i> , 2019, 36, 541-548.	2.7	4
11	The Smell of Death: An Unusual Case of Poisoning With the Organophosphorus Pesticide Chlorfenvinphos. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 250-252.	2.0	0
12	Multicenter, randomized controlled, observer-blinded study of a nitric oxide generating treatment in foot ulcers of patients with diabetes – ProNOx1 study. <i>Wound Repair and Regeneration</i> , 2018, 26, 228-237.	3.0	40
13	Association of genetic variation in telomere-related SNP and telomerase with ventricular arrhythmias in ischemic cardiomyopathy. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2018, 41, 261-266.	1.2	4
14	On the use of substandard medicines in hematology: An emerging concern in the Middle East and North Africa region. <i>European Journal of Internal Medicine</i> , 2018, 48, e40-e41.	2.2	2
15	Evaluation of analgesic effect and absorption of buprenorphine after buccal administration in cats with oral disease. <i>Journal of Feline Medicine and Surgery</i> , 2018, 20, 704-710.	1.6	13
16	Development of a Novel Multipenicillin Assay and Assessment of the Impact of Analyte Degradation: Lessons for Scavenged Sampling in Antimicrobial Pharmacokinetic Study Design. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	20
17	Utilization of data below the analytical limit of quantitation in pharmacokinetic analysis and modeling: promoting interdisciplinary debate. <i>Bioanalysis</i> , 2018, 10, 1229-1248.	1.5	17
18	Amenemvir: Studies of Potential CYP3A-Mediated Pharmacokinetic Interactions With Midazolam, Cyclosporine, and Ritonavir in Healthy Volunteers. <i>Clinical Pharmacology in Drug Development</i> , 2018, 7, 844-859.	1.6	7

#	ARTICLE	IF	CITATIONS
19	Amenomevir: Studies of Potential CYP2C8- and CYP2B6-Mediated Pharmacokinetic Interactions With Montelukast and Bupropion in Healthy Volunteers. <i>Clinical Pharmacology in Drug Development</i> , 2018, 7, 860-870.	1.6	6
20	A herbal treatment for type 2 diabetes adulterated with undisclosed drugs. <i>Lancet, The</i> , 2018, 391, 2411.	13.7	11
21	Cocoa flavanols reduce N-terminal pro-B-type natriuretic peptide in patients with chronic heart failure. <i>ESC Heart Failure</i> , 2016, 3, 97-106.	3.1	18
22	Effects of high flavanol dark chocolate on cardiovascular function and platelet aggregation. <i>Vascular Pharmacology</i> , 2015, 71, 70-78.	2.1	37
23	Substandard drugs: a potential crisis for public health. <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 218-243.	2.4	174
24	Cannabis use: a perspective in relation to the proposed UK drug-driving legislation. <i>Drug Testing and Analysis</i> , 2014, 6, 143-154.	2.6	17
25	Trends in less-lethal use of force techniques by police services within England and Wales: 2007-2011. <i>Forensic Science, Medicine, and Pathology</i> , 2014, 10, 50-55.	1.4	14
26	Development of HPLC-UV method for rapid and sensitive analysis of topically applied tetracaine: its comparison with a CZE method. <i>Biomedical Chromatography</i> , 2014, 28, 826-830.	1.7	6
27	Using tramadol to measure CYP2D6 metabolism in critically ill adults. <i>Intensive Care Medicine</i> , 2014, 40, 1177-1178.	8.2	6
28	The effectiveness of a novel neuromuscular electrostimulation method versus intermittent pneumatic compression in enhancing lower limb blood flow. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2014, 2, 160-165.	1.6	14
29	Acute effects of single-dose aripiprazole and haloperidol on resting cerebral blood flow (rCBF) in the human brain. <i>Human Brain Mapping</i> , 2013, 34, 272-282.	3.6	97
30	First reported case in the UK of acute prolonged neuropsychiatric toxicity associated with analytically confirmed recreational use of phenazepam. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 361-363.	1.9	18
31	Equivalence and interchangeability of narrow therapeutic index drugs in organ transplantation. <i>European Journal of Hospital Pharmacy</i> , 2013, 20, 302-307.	1.1	38
32	The Relevance of Factor VIII (FVIII) Pharmacokinetics to TDM and Hemophilia A Treatment: Is B Domain-Deleted FVIII Equivalent to Full-Length FVIII?. <i>Therapeutic Drug Monitoring</i> , 2012, 34, 110-117.	2.0	4
33	Integrating narrow therapeutic index drug formulations in transplantation. <i>European Journal of Hospital Pharmacy</i> , 2012, 19, 318-319.	1.1	0
34	Cost-effectiveness analysis of valsartan versus losartan and the effect of switching. <i>Journal of Medical Economics</i> , 2012, 15, 253-260.	2.1	4
35	Validation of self-reported khat chewing amongst khat chewers: An exploratory study. <i>Journal of Ethnopharmacology</i> , 2012, 140, 193-196.	4.1	13
36	"Ivory wave"™ toxicity in recreational drug users; integration of clinical and poisons information services to manage legal high poisoning. <i>Clinical Toxicology</i> , 2012, 50, 108-113.	1.9	27

#	ARTICLE	IF	CITATIONS
37	The differences between the branded and generic medicines using solid dosage forms: In-vitro dissolution testing. Results in Pharma Sciences, 2012, 2, 1-8.	4.2	30
38	Acute toxicity associated with the recreational use of the ketamine derivative methoxetamine. European Journal of Clinical Pharmacology, 2012, 68, 853-856.	1.9	106
39	A case series of individuals with analytically confirmed acute diphenyl-2-pyrrolidinemethanol (D2PM) toxicity. European Journal of Clinical Pharmacology, 2012, 68, 349-353.	1.9	20
40	Single oral doses of netazepide (<sc>YF</sc>476), a gastrin receptor antagonist, cause doseâ€dependent, sustained increases in gastric pH compared with placebo and ranitidine in healthy subjects. Alimentary Pharmacology and Therapeutics, 2012, 36, 181-189.	3.7	28
41	A survey to determine the views of renal transplant patients on generic substitution in the UK. Transplant International, 2011, 24, 770-779.	1.6	43
42	Generic and therapeutic substitution: a viewpoint on achieving best practice in Europe. British Journal of Clinical Pharmacology, 2011, 72, 727-730.	2.4	39
43	Development and Evaluation of a Composite Risk Score to Predict Kidney Transplant Failure. American Journal of Kidney Diseases, 2011, 57, 744-751.	1.9	43
44	Generic and therapeutic substitution: a response to our critic. International Journal of Clinical Pharmacy, 2011, 33, 881-881.	2.1	0
45	The Need for Standardization of Tacrolimus Assays. Clinical Chemistry, 2011, 57, 1739-1747.	3.2	55
46	The value of monitoring ciclosporin concentration 2 hours post-dose (C2) in dermatology: A prospective cohort study. Journal of Dermatological Treatment, 2011, 22, 79-85.	2.2	5
47	Plasma Clozapine and Norclozapine in Patients Prescribed Different Brands of Clozapine (Clozaril,) Tj ETQq1 1 0.784314 rgBT /Overlook	2.0	18
48	Generic and therapeutic substitutions: are they always ethical in their own terms?. International Journal of Clinical Pharmacy, 2010, 32, 691-695.	1.4	11
49	Effectiveness, safety and cost of drug substitution in hypertension. British Journal of Clinical Pharmacology, 2010, 70, 320-334.	2.4	47
50	Comparative Pharmacokinetic Assessments of Topical Drugs: Evaluation by Dermatopharmacokinetics, Microdialysis, and Systemic Measurement. Journal of Investigative Dermatology, 2010, 130, 2828-2830.	0.7	8
51	Augmentation of venous, arterial and microvascular blood supply in the leg by isometric neuromuscular stimulation via the peroneal nerve. International Journal of Angiology, 2010, 19, e31-e37.	0.6	74
52	THE EFFECTS OF HALOPERIDOL AND ARIPIPRAZOLE ON RESTING STATE BRAIN PERFUSION IN HEALTHY VOLUNTEERS. Schizophrenia Research, 2010, 117, 238-239.	2.0	0
53	Visual assessment of the timing of bruising by forensic experts. Journal of Clinical Forensic and Legal Medicine, 2010, 17, 143-149.	1.0	38
54	Challenges of therapeutic substitution of drugs for economic reasons: focus on CVD prevention. Current Medical Research and Opinion, 2010, 26, 871-878.	1.9	24

#	ARTICLE	IF	CITATIONS
55	Rapid analysis of tetracaine for a tape stripping pharmacokinetic study using short-end capillary electrophoresis. <i>Biomedical Chromatography</i> , 2009, 23, 488-491.	1.7	4
56	Pilot study to evaluate the efficacy and tolerability of levetiracetam (Keppra [®]) in treatment of patients with trigeminal neuralgia. <i>European Journal of Neurology</i> , 2009, 16, 740-744.	3.3	55
57	Convenient syntheses of the in vivo carbohydrate metabolites of mycophenolic acid: reactivity of the acyl glucuronide. <i>Tetrahedron Letters</i> , 2009, 50, 4973-4977.	1.4	6
58	Opportunities to Optimize Tacrolimus Therapy in Solid Organ Transplantation: Report of the European Consensus Conference. <i>Therapeutic Drug Monitoring</i> , 2009, 31, 139-152.	2.0	398
59	Comparison of the Predictive Performance of eGFR Formulae for Mortality and Graft Failure in Renal Transplant Recipients. <i>Transplantation</i> , 2009, 87, 384-392.	1.0	40
60	Intravenous Parecoxib Rapidly Leads to COX-2 Inhibitory Concentration of Valdecoxib in the Central Nervous System. <i>Clinical Pharmacology and Therapeutics</i> , 2008, 83, 430-435.	4.7	21
61	The Impact of Hemoglobin Levels on Patient and Graft Survival in Renal Transplant Recipients. <i>Transplantation</i> , 2008, 86, 564-570.	1.0	27
62	Cyclosporin in idiopathic glomerular disease associated with the nephrotic syndrome : Workshop recommendations. <i>Kidney International</i> , 2007, 72, 1429-1447.	5.2	166
63	Validation and application of capillary electrophoresis for the analysis of lidocaine in a skin tape stripping study. <i>Biomedical Chromatography</i> , 2007, 21, 775-779.	1.7	9
64	Multi-drug resistance gene-1 (MDR-1) haplotypes and the CYP3A5*1 genotype have no influence on ciclosporin dose requirements as assessed by C0 or C2 measurements. <i>Clinical Transplantation</i> , 2007, 21, 252-257.	1.6	31
65	Paradoxical Response to Tacrolimus Assessed by Interleukin-2 Gene Expression. <i>Transplantation Proceedings</i> , 2006, 38, 3327-3330.	0.6	4
66	Bioequivalence of Enteric-Coated Mycophenolate Sodium and Mycophenolate Mofetil: A Meta-Analysis of Three Studies in Stable Renal Transplant Recipients. <i>Transplantation</i> , 2006, 82, 1413-1418.	1.0	50
67	Study of a combined percutaneous local anaesthetic and the TDSR system for venepuncture. <i>Anaesthesia</i> , 2006, 61, 123-126.	3.8	3
68	Pharmacokinetics of a new testosterone transdermal delivery system, TDSR-testosterone in healthy males. <i>British Journal of Clinical Pharmacology</i> , 2006, 61, 275-279.	2.4	25
69	Renal Transplantation in Indo-Asian Patients in the UK. <i>American Journal of Transplantation</i> , 2006, 6, 761-769.	4.7	23
70	Influence of Donor C3 Allotype on Late Renal-Transplantation Outcome. <i>New England Journal of Medicine</i> , 2006, 354, 2014-2023.	27.0	176
71	Validation of High-Performance Liquid Chromatographic–Mass Spectrometric Method for the Analysis of Lidocaine in Human Plasma. <i>Journal of Chromatographic Science</i> , 2006, 44, 262-265.	1.4	14
72	Tacrolimus Pharmacogenetics: The CYP3A5*1 Allele Predicts Low Dose-Normalized Tacrolimus Blood Concentrations in Whites and South Asians. <i>Transplantation</i> , 2005, 79, 499-502.	1.0	178

#	ARTICLE	IF	CITATIONS
73	Analysis for Identification in Amnesty Bin Samples from Dance Venues. <i>Therapeutic Drug Monitoring</i> , 2005, 27, 793-798.	2.0	29
74	Risk Factors for Allograft Failure in United Kingdom Renal Transplant Recipients Treated with Cyclosporine A. <i>Transplantation</i> , 2005, 79, 953-957.	1.0	6
75	Seeking Optimal Prescription of Cyclosporine ME. <i>Therapeutic Drug Monitoring</i> , 2005, 27, 3-6.	2.0	11
76	Measurement Of Tacrolimus. Does The Choice Of Anticoagulant Matter?. <i>Therapeutic Drug Monitoring</i> , 2005, 27, 222.	2.0	1
77	Use of Neoral C2 monitoring: a European consensus. <i>Transplant International</i> , 2005, 18, 768-778.	1.6	59
78	Measurement of S-nitrosothiols in extracellular fluids from healthy human volunteers and rheumatoid arthritis patients, using electron paramagnetic resonance spectrometry. <i>Free Radical Biology and Medicine</i> , 2005, 39, 937-948.	2.9	34
79	CYP3A5 Genotype Does Not Influence the Blood Concentration of Tacrolimus Measured with the Abbott Immunoassay. <i>Clinical Chemistry</i> , 2005, 51, 2214-2215.	3.2	10
80	Circulation Time in Man from Lung to Periphery as an Indirect Index of Cardiac Output. , 2005, 566, 311-316.		5
81	Genotyping cytochrome P450 3A5 using the Light Cycler. <i>Annals of Clinical Biochemistry</i> , 2005, 42, 376-381.	1.6	19
82	Effective Synthesis of 1 ¹² -Acyl Glucuronides by Selective Acylation. <i>Organic Letters</i> , 2005, 7, 2591-2594.	4.6	43
83	Novel therapies in transplantation. <i>Expert Opinion on Investigational Drugs</i> , 2005, 14, 295-304.	4.1	14
84	A microparticle enzyme immunoassay to measure sirolimus. <i>Transplantation Proceedings</i> , 2005, 37, 182-184.	0.6	21
85	The Influence of Pharmacogenetics on the Time to Achieve Target Tacrolimus Concentrations after Kidney Transplantation. <i>American Journal of Transplantation</i> , 2004, 4, 914-919.	4.7	238
86	Potential clinical implications of substitution of generic cyclosporine formulations for cyclosporine microemulsion (Neoral) in transplant recipients. <i>European Journal of Clinical Pharmacology</i> , 2004, 60, 389-95.	1.9	24
87	The effects and metabolic fate of nitroflurbiprofen in healthy volunteers. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 76, 350-358.	4.7	14
88	Monitoring immunosuppressive drugs. <i>Handbook of Analytical Separations</i> , 2004, , 273-296.	0.8	1
89	Variable cyclosporine exposure: a risk factor for chronic allograft nephropathy and graft loss?. <i>Transplantation Proceedings</i> , 2004, 36, 1321-1326.	0.6	11
90	Early acute rejection does not affect chronic allograft nephropathy and death censored graft failure. <i>Transplantation Proceedings</i> , 2004, 36, 2993-2996.	0.6	9

#	ARTICLE	IF	CITATIONS
91	A survey to determine the blood concentration of cyclosporine 2 hours postdose in stable renal transplant patients. <i>Transplantation Proceedings</i> , 2004, 36, 3239-3241.	0.6	6
92	The relative proportions of sirolimus metabolites in blood using HPLC with mass-spectrometric detection. <i>Transplantation Proceedings</i> , 2004, 36, 3223-3225.	0.6	21
93	Patient management by cyclosporine C2 monitoring. <i>Transplantation</i> , 2004, 77, 323-324.	1.0	5
94	Monitoring Immunosuppressive Drugs. <i>Therapeutic Drug Monitoring</i> , 2004, 26, 244-247.	2.0	6
95	A new low-dose formulation of selegiline: clinical efficacy, patient preference and selectivity for MAO-B inhibition. <i>Journal of Neural Transmission</i> , 2003, 110, 1257-1271.	2.8	52
96	Longitudinal evaluation of the pharmacokinetics of cyclosporin microemulsion (Neoral [®]) in pediatric renal transplant recipients and assessment of C2 level as a marker for absorption. <i>Pediatric Transplantation</i> , 2003, 7, 282-288.	1.0	50
97	The TMC study. <i>Lancet</i> , The, 2003, 361, 346-347.	13.7	0
98	A pharmacokinetic and clinical review of the potential clinical impact of using different formulations of cyclosporin A. <i>Clinical Therapeutics</i> , 2003, 25, 1654-1669.	2.5	67
99	Re: Drugs, driving and sobriety tests. <i>Journal of Clinical Forensic and Legal Medicine</i> , 2003, 10, 126-127.	0.8	1
100	Monitoring Cyclosporin in Blood: Between-Assay Differences at Trough and 2 Hours Post-dose (C2). <i>Therapeutic Drug Monitoring</i> , 2003, 25, 167-173.	2.0	48
101	Oral Hydrocortisone Administration in Children with Classic 21-Hydroxylase Deficiency Leads to More Synchronous Joint GH and Cortisol Secretion. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 2238-2244.	3.6	21
102	Recommendations for the Implementation of Neoral C2 Monitoring in Clinical Practice. <i>Transplantation</i> , 2002, 73, S19-S22.	1.0	76
103	Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and p-glycoprotein correlate with dose requirement. <i>Transplantation</i> , 2002, 74, 1486-1489.	1.0	283
104	Effects of repeated oral doses of TAK-013, a new non-peptide gonadotropin-releasing hormone (GnRH) antagonist, in healthy pre-menopausal women. <i>Fertility and Sterility</i> , 2002, 78, S280-S281.	1.0	2
105	Effects of single and repeated oral doses of TAK-013, a new non-peptide gonadotropin-releasing hormone (GnRH) antagonist, in healthy post-menopausal women. <i>Fertility and Sterility</i> , 2002, 78, S281-S282.	1.0	9
106	Therapeutic drug monitoring of immunosuppressant drugs in clinical practice. <i>Clinical Therapeutics</i> , 2002, 24, 330-350.	2.5	264
107	Pharmacokinetics of oral cyclosporine (Neoral) in heart transplant recipients during the immediate period after surgery. <i>Transplant International</i> , 2002, 15, 649-654.	1.6	16
108	Influence of albumin supplementation on tacrolimus and cyclosporine therapy early after liver transplantation. <i>Liver Transplantation</i> , 2002, 8, 224-232.	2.4	24

#	ARTICLE	IF	CITATIONS
109	Pharmacokinetics of oral cyclosporine (Neoral) in heart transplant recipients during the immediate period after surgery. <i>Transplant International</i> , 2002, 15, 649-654.	1.6	10
110	A new method to monitor drugs at dance venues. <i>BMJ: British Medical Journal</i> , 2001, 323, 603-603.	2.3	31
111	Noeral C-2 monitoring in cardiac transplant patients. <i>Transplantation Proceedings</i> , 2001, 33, 1572-1575.	0.6	16
112	Limited Sampling Strategies for Estimating Cyclosporin Area Under the Concentration-Time Curve: Review of Current Algorithms. <i>Therapeutic Drug Monitoring</i> , 2001, 23, 100-114.	2.0	114
113	Cyclosporin Measurement – who cares about inaccuracy?. <i>Accreditation and Quality Assurance</i> , 2001, 6, 405-408.	0.8	10
114	Oxidative stress could precede endothelial dysfunction and insulin resistance in Indian Mauritians with impaired glucose metabolism. <i>Diabetologia</i> , 2001, 44, 706-712.	6.3	133
115	Immunosuppressant drugs – the role of therapeutic drug monitoring. <i>British Journal of Clinical Pharmacology</i> , 2001, 52, 61-73.	2.4	5
116	Immunosuppressant drugs – the role of therapeutic drug monitoring. <i>British Journal of Clinical Pharmacology</i> , 2001, 52, 61-73.	2.4	36
117	Plasma Nitrate Concentrations in Children with Infectious and Noninfectious Diarrhea. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2001, 32, 423-427.	1.8	15
118	Bioavailability of oral hydrocortisone in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. <i>Journal of Endocrinology</i> , 2001, 169, 65-70.	2.6	92
119	Serum Cortisol and 17-Hydroxyprogesterone Interrelation in Classic 21-Hydroxylase Deficiency: Is Current Replacement Therapy Satisfactory?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 4679-4685.	3.6	76
120	Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency: Alterations in Cortisol Pharmacokinetics at Puberty. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 2701-2708.	3.6	108
121	Serum Cortisol and 17-Hydroxyprogesterone Interrelation in Classic 21-Hydroxylase Deficiency: Is Current Replacement Therapy Satisfactory?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 4679-4685.	3.6	17
122	Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency: Alterations in Cortisol Pharmacokinetics at Puberty. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 2701-2708.	3.6	22
123	Accuracy of Cyclosporin Measurements Made in Capillary Blood Samples Obtained by Skin Puncture. <i>Therapeutic Drug Monitoring</i> , 2000, 22, 594-598.	2.0	44
124	Pharmacokinetics of mycophenolate mofetil in patients with end-stage renal failure. <i>Kidney International</i> , 2000, 57, 1164-1168.	5.2	58
125	Validation of an Assay for Routine Monitoring of Sirolimus Using HPLC with Mass Spectrometric Detection. <i>Clinical Chemistry</i> , 2000, 46, 1179-1183.	3.2	83
126	New Approaches to Cyclosporine Monitoring Raise Further Concerns about Analytical Techniques. <i>Clinical Chemistry</i> , 2000, 46, 872-874.	3.2	51

#	ARTICLE	IF	CITATIONS
127	Nitric oxide synthesis and isoprostane production in subjects with type 1 diabetes and normal urinary albumin excretion. <i>Diabetes</i> , 2000, 49, 857-862.	0.6	59
128	Measurement of sirolimus in whole blood using high-performance liquid chromatography with ultraviolet detection. <i>Clinical Therapeutics</i> , 2000, 22, B38-B48.	2.5	52
129	An immunoassay for the measurement of sirolimus. <i>Clinical Therapeutics</i> , 2000, 22, B49-B61.	2.5	52
130	Proficiency-testing issues relating to sirolimus. <i>Clinical Therapeutics</i> , 2000, 22, B122-B132.	2.5	21
131	Neoral absorption profiling: an evolution in effectiveness. <i>Transplantation Proceedings</i> , 2000, 32, S45-S52.	0.6	86
132	The impact of cyclosporin formulation on clinical outcomes. <i>Transplantation Proceedings</i> , 2000, 32, 1552-1555.	0.6	3
133	Impact of Absorption Profiling on Efficacy and Safety of Cyclosporin Therapy in Transplant Recipients. <i>Clinical Pharmacokinetics</i> , 2000, 39, 117-125.	3.5	100
134	Effects of Recombinant Human Insulin-Like Growth Factor I (IGF-I) Therapy on the Growth Hormone-IGF System of a Patient with a Partial IGF-I Gene Deletion. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 1611-1616.	3.6	67
135	Therapeutic drug monitoring of immunosuppressant drugs. <i>British Journal of Clinical Pharmacology</i> , 1999, 47, 339-350.	2.4	65
136	Death rate from use of ecstasy or heroin. <i>Lancet</i> , The, 1999, 354, 2166.	13.7	8
137	Bioequivalence criteria for cyclosporine. <i>Transplantation Proceedings</i> , 1999, 31, 1649-1653.	0.6	17
138	Optimization of cyclosporine therapy with new therapeutic drug monitoring strategies: report from the international neoral [®] tdm advisory consensus meeting (vancouver, november 1997). <i>Transplantation Proceedings</i> , 1998, 30, 1645-1649.	0.6	72
139	Generic substitution for cyclosporine: what should we be looking for in new formulations?. <i>Transplantation Proceedings</i> , 1998, 30, 1652-1653.	0.6	12
140	Evidence for a Difference in Nitric Oxide Biosynthesis Between Healthy Women and Men. <i>Hypertension</i> , 1998, 32, 730-734.	2.7	196
141	Monitoring New Immunosuppressive Agents Are the Methods Adequate?. <i>Drug Metabolism and Drug Interactions</i> , 1997, 14, 5-16.	0.3	18
142	Cyclosporin Microemulsion. <i>BioDrugs</i> , 1997, 7, 175-197.	4.6	20
143	Variable Bioavailability of Oral Melatonin. <i>New England Journal of Medicine</i> , 1997, 336, 1028-1029.	27.0	111
144	Tacrolimus Quality Assessment. <i>Therapeutic Drug Monitoring</i> , 1997, 19, 243.	2.0	3

#	ARTICLE	IF	CITATIONS
145	Simple Bioequivalence Criteria. Therapeutic Drug Monitoring, 1997, 19, 375-381.	2.0	47
146	Aspartame Pharmacokineticsâ€™The Effect of Ageing. Age and Ageing, 1996, 25, 217-220.	1.6	8
147	Quality Assessment Issues of New Immunosuppressive Drugs and Experimental Experience. Therapeutic Drug Monitoring, 1996, 18, 362-367.	2.0	24
148	Cyclosporin A: Analytical Methodology and Factors Affecting Therapeutic Drug Monitoring. Therapeutic Drug Monitoring, 1995, 17, 625-630.	2.0	28
149	Pharmacokinetics of Orally Administered Cyclosporine in Patients with Crohn's Disease. Journal of Clinical Pharmacology, 1995, 35, 681-687.	2.0	15
150	Concentration-Controlled Trials. Clinical Pharmacokinetics, 1995, 28, 93-99.	3.5	23
151	Effect of grapefruit juice on blood cyclosporin concentration. Lancet, The, 1995, 346, 122-124.	13.7	24
152	Fraud in medical science. Lancet, The, 1995, 346, 378.	13.7	1
153	Methodological and Clinical Aspects of Cyclosporin Monitoring: Report of the Association of Clinical Biochemists Task Force. Annals of Clinical Biochemistry, 1994, 31, 420-446.	1.6	72
154	Effect of Terbinafine on the Pharmacokinetics of Cyclosporin in Humans. Journal of Investigative Dermatology, 1994, 102, 740-743.	0.7	19
155	Pharmacokinetics of naftopidil, a novel anti-hypertensive drug, in patients with hepatic dysfunction. Postgraduate Medical Journal, 1994, 70, 363-366.	1.8	18
156	Lack of effect of interferon Î±2a upon fluorouracil pharmacokinetics. British Journal of Cancer, 1994, 70, 724-728.	6.4	27
157	Influence of lornoxicam a new non-steroidal antiinflammatory drug on lithium pharmacokinetics. Human Psychopharmacology, 1993, 8, 289-292.	1.5	4
158	Influence of debrisoquine hydroxylation phenotype on the pharmacokinetics of mexiletine. European Journal of Clinical Pharmacology, 1993, 44, 63-67.	1.9	25
159	Pharmacokinetics of Cyclosporine and Steadyâ€™State Aspirin During Coadministration. Journal of Clinical Pharmacology, 1993, 33, 513-521.	2.0	6
160	A pharmacokinetic interaction between cimetidine or ranitidine and lornoxicam.. Postgraduate Medical Journal, 1993, 69, 865-866.	1.8	9
161	Determination of Oxidation Phenotype by Measurement of Propafenone Urinary Metabolic Ratios. Human and Experimental Toxicology, 1993, 12, 161-163.	2.2	0
162	Quality Assurance Programs for Immunosuppressive Drugs. Therapeutic Drug Monitoring, 1993, 15, 472-477.	2.0	9

#	ARTICLE	IF	CITATIONS
163	Pharmacokinetics of Cyclosporine and Multiple-Dose Diclofenac During Coadministration. <i>Journal of Clinical Pharmacology</i> , 1993, 33, 936-943.	2.0	25
164	Does Bismuth Chelate Influence Lornoxicam Absorption?. <i>Human and Experimental Toxicology</i> , 1992, 11, 59-60.	2.2	3
165	Cyclosporin monitoring: Its role in autoimmune indications. <i>Journal of Autoimmunity</i> , 1992, 5, 177-182.	6.5	13
166	Treatment of severe refractory atopic dermatitis with cyclosporin. <i>Lancet, The</i> , 1991, 338, 643-644.	13.7	3
167	Cyclosporin and vitamin E. <i>Lancet, The</i> , 1991, 338, 697.	13.7	5
168	Plasma metronidazole concentrations after single and repeated vaginal pessary administration.. <i>British Journal of Clinical Pharmacology</i> , 1991, 32, 621-623.	2.4	4
169	Hepatic β_2 -adrenoceptor adaptation during propranolol administration is impaired in ageing rats. <i>European Journal of Pharmacology</i> , 1991, 208, 323-330.	2.6	2
170	The effect of age on the pharmacokinetics of pentisomide. <i>Biopharmaceutics and Drug Disposition</i> , 1991, 12, 627-631.	1.9	3
171	Monitoring cyclosporin: is it still important?. <i>Immunology Letters</i> , 1991, 29, 99-103.	2.5	10
172	The Effect of Repeated Oral Doses of Lornoxicam on Antipyrine Elimination in Normal Human Volunteers. <i>Human and Experimental Toxicology</i> , 1991, 10, 375-377.	2.2	6
173	Tolerability and Kinetics of Intravenous Medifoxamine in Healthy Volunteers. <i>International Clinical Psychopharmacology</i> , 1990, 5, 97-102.	1.7	2
174	Stability of plasma amiodarone levels during chronic oral therapy. <i>Cardiovascular Drugs and Therapy</i> , 1990, 4, 529-530.	2.6	4
175	Measurement of medifoxamine metabolites in urine by high-performance liquid chromatography. <i>Biomedical Applications</i> , 1990, 528, 531-536.	1.7	2
176	Medifoxamine: Oral tolerance and pharmacokinetic study in healthy human volunteers. <i>European Journal of Clinical Pharmacology</i> , 1990, 39, 169-171.	1.9	5
177	An examination of a possible pharmacokinetic interaction between nifedipine and antipyrine. <i>European Journal of Clinical Pharmacology</i> , 1990, 39, 405-407.	1.9	5
178	Automatic on-line extraction coupled with electrochemical detection as an improved method for the HPLC co-analysis of codeine and morphine in plasma and gastric juice. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 1990, 8, 1021-1027.	2.8	5
179	Consensus Document: Hawk's Cay Meeting on Therapeutic Drug Monitoring of Cyclosporine. <i>Clinical Chemistry</i> , 1990, 36, 1510-1516.	3.2	132
180	A Study of the Interaction between Lornoxicam and Warfarin in Healthy Volunteers. <i>Human and Experimental Toxicology</i> , 1990, 9, 413-414.	2.2	16

#	ARTICLE	IF	CITATIONS
181	Lornoxicam, indomethacin and placebo: comparison of effects on faecal blood loss and upper gastrointestinal endoscopic appearances in healthy men.. Postgraduate Medical Journal, 1990, 66, 622-626.	1.8	13
182	Cyclosporin assay techniques. Accuracy and reproducibility variables impacting on measurements. International Journal of Radiation Applications and Instrumentation Part B, Nuclear Medicine and Biology, 1990, 17, 733-736.	0.3	6
183	Absolute bioavailability and pharmacokinetics of medifoxamine in healthy humans.. British Journal of Clinical Pharmacology, 1990, 30, 621-624.	2.4	3
184	Letter to the Editor. Human Toxicology, 1989, 8, 53-54.	0.9	3
185	Pharmacokinetic Interaction Between Indoramin and Ethanol. Human Toxicology, 1989, 8, 237-241.	0.9	6
186	Effects of amiodarone on the kinetics of antipyrine. American Journal of Cardiology, 1989, 63, 991-992.	1.6	3
187	The digoxin-amiodarone interaction. Cardiovascular Drugs and Therapy, 1989, 3, 25-28.	2.6	37
188	Determination of medifoxamine in plasma and urine by high-performance liquid chromatography. Biomedical Applications, 1989, 496, 223-227.	1.7	3
189	The relationship between theophylline clearance and age in adult life. European Journal of Clinical Pharmacology, 1989, 36, 29-34.	1.9	18
190	Pharmacokinetics of dextropropoxyphene and nordextropropoxyphene in young and elderly volunteers after single and multiple dextropropoxyphene dosage.. British Journal of Clinical Pharmacology, 1989, 28, 463-469.	2.4	27
191	A psychopharmacological study to assess anti-muscarinic and central nervous effects of medifoxamine in normal volunteers. Human Psychopharmacology, 1988, 3, 195-200.	1.5	6
192	RELATIVE BIOAVAILABILITY OF CONTROLLED RELEASE MORPHINE TABLETS (MST CONTINUS) IN CANCER PATIENTS. British Journal of Anaesthesia, 1988, 61, 569-574.	3.4	46
193	The influence of haematocrit on blood cyclosporin measurements in vivo.. British Journal of Clinical Pharmacology, 1988, 25, 509-513.	2.4	11
194	A comparison of bisoprolol and atenolol in the treatment of mild to moderate hypertension.. British Journal of Clinical Pharmacology, 1988, 26, 53-59.	2.4	10
195	Circadian variation in theophylline absorption during chronic dosing with a slow release theophylline preparation and the effect of clock time of dosing.. British Journal of Clinical Pharmacology, 1988, 26, 73-77.	2.4	8
196	CYCLOSPORIN RADIOIMMUNOASSAY AND CARDIAC TRANSPLANTATION. Lancet, The, 1988, 332, 459.	13.7	0
197	Pharmacokinetics of flupirtine in elderly volunteers and in patients with moderate renal impairment. Postgraduate Medical Journal, 1988, 64, 361-363.	1.8	19
198	A Study of the Interaction between Oxytetracycline and Pyridostigmine. Human Toxicology, 1988, 7, 263-266.	0.9	5

#	ARTICLE	IF	CITATIONS
199	Chlortenoxicam pharmacokinetics in young and elderly human volunteers.. Postgraduate Medical Journal, 1988, 64, 752-754.	1.8	27
200	Comparison of flupirtine and indomethacin on frusemide-induced diuresis. Postgraduate Medical Journal, 1987, 63, 959-961.	1.8	2
201	The interaction between chronic oral slow-release theophylline and single-dose intravenous erythromycin. Xenobiotica, 1987, 17, 493-497.	1.1	2
202	The analysis of dose-response curves—a practical approach.. British Journal of Clinical Pharmacology, 1987, 23, 199-205.	2.4	6
203	Plasma flecainide concentrations following acute myocardial infarction. International Journal of Cardiology, 1987, 15, 341-346.	1.7	2
204	Subcutaneous infusion of bleomycin—a practical alternative to intravenous infusion.. Journal of Clinical Oncology, 1987, 5, 648-650.	1.6	3
205	The effect of vehicle on the oral absorption of cyclosporin.. British Journal of Clinical Pharmacology, 1986, 21, 331-333.	2.4	25
206	The bioavailability and pharmacokinetics of slow release nifedipine during chronic dosing in volunteers.. British Journal of Clinical Pharmacology, 1986, 21, 385-388.	2.4	13
207	The interaction between i.v. theophylline and chronic oral dosing with slow release nifedipine in volunteers.. British Journal of Clinical Pharmacology, 1986, 21, 389-392.	2.4	17
208	The United Kingdom Cyclosporin Quality Assessment Scheme. Therapeutic Drug Monitoring, 1986, 8, 200-204.	2.0	31
209	The effect of dose on the bioavailability of oral etoposide. Cancer Chemotherapy and Pharmacology, 1986, 16, 178-81.	2.3	42
210	The acute changes in serum binding of disopyramide and flecainide after myocardial infarction. European Journal of Clinical Pharmacology, 1985, 28, 253-255.	1.9	19
211	The relationship between clearance of theophylline and age within the adult age range. European Journal of Clinical Pharmacology, 1985, 29, 177-179.	1.9	7
212	High-performance liquid chromatography of etoposide in plasma and urine. Biomedical Applications, 1985, 339, 419-423.	1.7	32
213	The effect of food and concurrent chemotherapy on the bioavailability of oral etoposide. British Journal of Cancer, 1985, 52, 363-367.	6.4	33
214	Concentration of d-propranolol in cervico-vaginal mucus: targeting of a novel spermicide. Advances in Contraception: the Official Journal of the Society for the Advancement of Contraception, 1985, 1, 103-108.	0.3	5
215	Variable bioavailability following repeated oral doses of etoposide. European Journal of Cancer & Clinical Oncology, 1985, 21, 1315-1319.	0.7	59
216	Flecainide pharmacokinetics in healthy volunteers: the influence of urinary pH.. British Journal of Clinical Pharmacology, 1985, 20, 333-338.	2.4	25

#	ARTICLE	IF	CITATIONS
217	simp: A computer program in basic for nonlinear curve fitting. Journal of Pharmacological Methods, 1985, 14, 323-329.	0.7	34
218	The disposition of inhaled lysine theophylline in volunteers. European Journal of Clinical Pharmacology, 1984, 26, 635-637.	1.9	0
219	Delayed-release bleomycin. Cancer Chemotherapy and Pharmacology, 1984, 13, 19-21.	2.3	8
220	The efficiency of protective gloves used in the handling of cytotoxic drugs. Cancer Chemotherapy and Pharmacology, 1984, 12, 151-3.	2.3	24
221	The bioavailability of oral intermediate-dose methotrexate. Cancer Chemotherapy and Pharmacology, 1984, 13, 91-4.	2.3	12
222	The pharmacokinetics of subcutaneous bolus cytosine arabinoside in an arachis oil plus aluminium distearate suspension. Investigational New Drugs, 1984, 2, 271-6.	2.6	4
223	The influence of urinary pH on flecainide excretion and its serum pharmacokinetics.. British Journal of Clinical Pharmacology, 1984, 17, 447-451.	2.4	30
224	Is circadian variation in theophylline trough serum concentrations determined by time of dosing?. British Journal of Clinical Pharmacology, 1984, 17, 777-779.	2.4	11
225	The influence of cimetidine on the pharmacokinetics of 5-fluorouracil.. British Journal of Clinical Pharmacology, 1984, 18, 421-430.	2.4	52
226	CONCENTRATION OF D-PROPRANOLOL IN CERVICOVAGINAL MUCUS. Lancet, The, 1984, 324, 1480.	13.7	9
227	Subcutaneous infusion of cytosine arabinoside. Cancer Chemotherapy and Pharmacology, 1983, 10, 112-114.	2.3	12
228	STRIFE: An interactive computer program for the analysis of drug pharmacokinetics. Journal of Pharmacological Methods, 1983, 9, 193-199.	0.7	118
229	The pharmacokinetics of lysine theophylline, a new soluble theophylline, in human volunteers.. Postgraduate Medical Journal, 1983, 59, 86-87.	1.8	8
230	Oral theophylline in chronic heart failure. Postgraduate Medical Journal, 1982, 58, 216-221.	1.8	3
231	Cytosine arabinoside: pharmacokinetics following different routes of administration. Biochemical Society Transactions, 1982, 10, 512-513.	3.4	0
232	Saliva theophylline concentrations after a single oral dose.. British Journal of Clinical Pharmacology, 1982, 13, 243-245.	2.4	9
233	Pharmacokinetic interaction between theophylline and erythromycin.. British Journal of Clinical Pharmacology, 1982, 14, 495-499.	2.4	34
234	Systemic availability of oral verapamil and effect on PR interval in man.. British Journal of Clinical Pharmacology, 1981, 12, 397-400.	2.4	46

#	ARTICLE	IF	CITATIONS
235	The pharmacokinetics of subcutaneous cytosine arabinoside in patients with acute myelogenous leukaemia.. British Journal of Clinical Pharmacology, 1981, 12, 507-510.	2.4	22
236	A single-dose comparison of four slow-release theophylline preparations in normal subjects. Postgraduate Medical Journal, 1981, 57, 153-155.	1.8	13
237	Rapid high-performance liquid chromatographic method for the measurement of verapamil and norverapamil in blood plasma or serum. Journal of Chromatography A, 1981, 218, 621-629.	3.7	72
238	Mexiletine in human blood and breast milk.. Postgraduate Medical Journal, 1981, 57, 546-547.	1.8	36
239	Pharmacokinetics of oral disopyramide phosphate in patients with renal impairment.. British Journal of Clinical Pharmacology, 1980, 10, 245-248.	2.4	31
240	Influence of renal failure on disopyramide pharmacokinetics [proceedings]. British Journal of Clinical Pharmacology, 1979, 7, 427P-428P.	2.4	3
241	The measurement of lignocaine at low concentrations in plasma, a comparison of gas liquid chromatography with enzyme immunoassay.. British Journal of Clinical Pharmacology, 1979, 8, 598-599.	2.4	10
242	The effect of spontaneous changes in urinary pH on mexiletine plasma concentrations and excretion during chronic administration to healthy volunteers.. British Journal of Clinical Pharmacology, 1979, 8, 349-352.	2.4	26
243	Pharmacodynamic studies of verapamil after oral and i.v. administration in man [proceedings]. British Journal of Clinical Pharmacology, 1979, 8, 397P-398P.	2.4	2
244	Gas-liquid chromatographic method for the routine estimation of disopyramide in plasma or serum. Journal of Chromatography A, 1978, 152, 501-506.	3.7	13
245	The systemic availability of a slow release rectal preparation of lignocaine [proceedings]. British Journal of Clinical Pharmacology, 1978, 6, 442P-443P.	2.4	4